Trialbee Secures Majority Investment to Revolutionize Clinical Trials

Clinical trial recruitment specialist Trialbee has obtained a majority investment from Varsity Healthcare Partners, a move that positions the company to enhance its technology and expand its global reach. This investment occurs at a time when biopharmaceutical companies are facing increasing challenges related to trial enrollment complexities. Financial details of the deal have not been disclosed, but it grants Varsity Healthcare Partners a controlling stake in the company, while existing investors MTIP and Industrifonden will retain minority stakes.

The new funding will enable Trialbee to accelerate the growth of its Honey Platform, expand its enterprise-level recruitment services, and improve international operations within its omnichannel partner ecosystem. The company is strategically situated at the nexus of patient identification, feasibility analysis, and site engagement, an area that has become increasingly pressured as sponsors encounter delays that can add years and substantial costs to drug development.

Matt Walz, Chief Executive Officer of Trialbee, emphasized that this partnership will enhance the company’s capacity to deliver timely and predictable outcomes for sponsors, contract research organizations, and trial sites globally. The objective is to connect patients with research sites more accurately, thereby facilitating on-time and budget-compliant study enrollments.

Over the past year, Trialbee has significantly broadened its global presence, collaborating with over 6,000 research sites across 50 countries and supporting trials in 66 languages. The company reported screening more than 1.5 million patients in 2025, thanks to new sponsor-specific registries and enhanced data partnerships aimed at improving patient-aligned feasibility and enrollment estimates.

The investment aligns with Varsity Healthcare Partners’ focus on supporting healthcare services and technology businesses that enhance clinical operations at scale. Partner Navid Gharavi expressed that the firm was attracted to Trialbee’s commitment to customer outcomes and its innovative use of data and analytics to tackle one of the most persistent issues in clinical research.

This investment arrives as biopharmaceutical sponsors are under increased scrutiny regarding trial timelines and enrollment performance. With protocols becoming more specialized and eligibility criteria tightening, recruitment failures have emerged as a leading cause of trial delays and cost overruns.

Trialbee has stated that both its leadership team and mission will remain unchanged as it embarks on this new growth phase. Financial advisory firm Stout provided guidance to Trialbee during this transaction. With the infusion of new capital and a majority owner, Trialbee is positioning itself as a vital infrastructure partner for sponsors aiming to modernize how patients are identified, engaged, and enrolled in clinical trials around the world.